Treatment Registry
TR-0593 ActiveRecorded September 2026

Compounded tirzepatide

Sold by Next Vial · Injection, vial · every compounded tirzepatide record

Recorded initial charges

First month

$249.97

first month, including required fees on record. The published monthly rate excludes one-time and annual fees; introductory and conditional rates may change. Some fee details are unverified or unpublished; this sum does not establish the full amount payable.

Medication · Starting price (shared listing with semaglutide, not broken out by drug) · recorded initial monthly payment$249.97

Added from the figures recorded below.

Price

TermPer monthCharged today
Starting price (shared listing with semaglutide, not broken out by drug)

“Doctor-Led Weight Loss Plans as Low as $249.97/Month Provider personalized dosages, one all-in price.”

Per month$249.97Charged today$249.97
Price sources
Visit Next Vial

We earn nothing from this link. It opens Next Vial's website without a paid referral.

History

Fewer than two comparable calendar-month readings are available for a price trend. Day- or week-based supplies, introductory offers and unverified payment terms are not connected in this chart.

  • September 2026 — Entry added to the register

Sourcing and terms

PharmacyManifest Pharmacy, Greer SC
StatesAll states except Alaska
PrescriberBoth
CancellationLogin to your Next Vial account and reorder or cancel at any time. You will be contacted before your medication is to be refilled and billed to your credit card.

Not yet checked: membership and consult fee.

Recorded from nextvial.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.

Notes

  1. 1. September 2026 — The single product page has a medication selector toggling between 'Semaglutide Injection' and 'Tirzepatide Injection' but only ever displays one shared starting price ($249.97/mo) rather than a price for each drug separately, so the same figure was recorded for both with a note in the label. The FAQ's 'Next Vial currently serves patients in the following states:' sentence is followed by what is evidently a dynamic list/map widget that never rendered as text, so no actual state list could be read. 'No Membership' is stated explicitly on the homepage.

Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.

This record

Entry
TR-0593
Medication category
compounded tirzepatide
Readings
1

Related records

Other records from Next Vial

All Next Vial programs and terms

Compounded tirzepatide at a similar price

The records either side of this one in the recorded spread. Not a ranking, and not a recommendation — a position among 374 records of the same molecule.

Cite this entry

Treatment Registry. (2026). Next Vial — compounded tirzepatide (TR-0593). Last verified September 2026. Retrieved [your access date], from https://treatmentregistry.com/registry/TR-0593

Replace the bracket with the date you read it. Ours is the date we last checked the figures, which is a different thing and is given separately.